Schizophrenia and bipolar disorder are severe psychiatric disorders that are frequently associated with persistent symptoms and significant dysfunction. While there are a multitude of psychopharmacologic agents are available for treatment of these illnesses, suboptimal response and significant adverse consequences limit their utility. Cariprazine is a new, novel antipsychotic medication with dopamine D2 and D3 partial agonist effects. Its safety and efficacy have been investigated in acute psychosis of schizophrenia, bipolar mania, bipolar depression, and unipolar depression. Efficacy has been demonstrated in schizophrenia and mania. It is unclear if cariprazine is effective in depression associated with unipolar or bipolar illness. Adverse consequences include extrapyramidal symptoms including akathisia, and various gastrointestinal symptoms. The US Food and Drug Administration (FDA) has recently approved cariprazine. This review will provide clinicians with basic information regarding the research program of cariprazine.
Digital Object Identifier (DOI)
Dr Rif S El-Mallakh has grant funding from the National Institute of Mental Health, the State of Kentucky, Merck, Teva, and Psychnostics
Roberts, Rona Jeannie; Findlay, Lillian Jan; El-Mallakh, Peggy; and El-Mallakh, Rif S., "Update on Schizophrenia and Bipolar Disorder: Focus on Cariprazine" (2016). Nursing Faculty Publications. 28.